Emesis Clinical Trial
Official title:
Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-blind Randomized Study
The aim of the study is to compare efficacy and tolerability of aprepitant versus dexamethasone in the prevention of delayed emesis induced by moderately emetogenic chemotherapy (cyclophosphamide plus anthracyclines) in breast cancer patients.
This is a phase III, double-blind, randomized trial, to evaluated the efficacy and safety of
aprepitant for the prevention of delayed emesis in patients with breast cancer submitted for
the first time to chemotherapy with cyclophosphamide plus anthracyclines.
The study will be carried out during the first cycle of chemotherapy.
For the prevention of acute emesis, all patients will receive, before chemotherapy:
- dexamethasone 8 mg iv in 15 minutes, 30 minutes before chemotherapy;
- palonosetron 0.25 mg iv bolus, 30 minutes before chemotherapy
- aprepitant 125 mg orally, 60 minutes before chemotherapy
After 24 hours from chemotherapy administration, patients will be randomized to receive:
A) dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am
and 8 pm on day 3.
B) Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
The patients will receive prochlorperazine suppositories as rescue medication, for important
nausea and vomiting (> 2 episodes) during days 1-5 after chemotherapy.
The patients will receive a diary, which includes a Visual Analogue Scale (VAS) for nausea
and vomiting evaluation. All patients will fill out the diary in which, for 6 consecutive
days (days 1-6), patients will report for each day the number of vomiting episodes, the
intensity and duration of nausea, any antiemetic rescue medication and any adverse event and
its treatment.
In addition, on day 1 before chemotherapy and then on day 6, patients will fill out the FLIE
(Functional Living Index-Emesis), a questionnaire concerning the impact of nausea and
vomiting on their quality of life.
Primary end point is the percentage of complete responses (no vomiting and no rescue
treatment) on days 2-5 after chemotherapy administration
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01913990 -
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
|
Phase 4 | |
Terminated |
NCT00869310 -
Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis
|
Phase 3 | |
Completed |
NCT04719286 -
MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy
|
N/A | |
Completed |
NCT01046240 -
Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT03478605 -
Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
|
Phase 2 | |
Recruiting |
NCT04564144 -
Evaluation of Meclizine Orodispersible Tablet Pharmacokinetic in Human Volunteers
|
Phase 1/Phase 2 | |
Completed |
NCT01509417 -
Different Feeding Methods After Pyloromyotomy
|
N/A | |
Terminated |
NCT01148264 -
Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis
|
Phase 2 | |
Completed |
NCT00152867 -
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy
|
Phase 3 | |
Completed |
NCT04182750 -
Promoting Safe Medication Use in Pregnancy in the Era of Real-World Data - The SafeStart Study
|
N/A | |
Completed |
NCT02980289 -
DAnish Nausea Study In Advanced Cancer-Epidemiology: A Danish Multicenter Trial to Investigate the Prevalence and Treatment of Nausea and/or Vomiting in Patients With Advanced Cancer.
|
||
Completed |
NCT02602080 -
Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia
|
||
Completed |
NCT04585841 -
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
|
Phase 1 | |
Completed |
NCT01414478 -
High Protein Intake to Decrease Emesis and Promote Patient Satisfaction in Labor
|
N/A | |
Not yet recruiting |
NCT02407600 -
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
|
Phase 2 |